Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: END086
MIFTS: 51

End Stage Renal Disease

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for End Stage Renal Disease

About this section

MalaCards integrated aliases for End Stage Renal Disease:

Name: End Stage Renal Disease 12 15
End Stage Renal Failure 12 15
End-Stage Kidney Disease 12

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:783
ICD9CM 34 585.6
Sources

Summaries for End Stage Renal Disease

About this section
Disease Ontology : 12 A chronic kidney disease is characterized by non-functioning kidneys, as the final stage in chronic kidney disease.

MalaCards based summary : End Stage Renal Disease, also known as end stage renal failure, is related to microvascular complications of diabetes 3 and alport syndrome. An important gene associated with End Stage Renal Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics and Complement and coagulation cascades. The drugs Capsaicin and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Kidney failure, also known as end-stage kidney disease, is a medical condition in which the kidneys are... more...

Sources

Related Diseases for End Stage Renal Disease

About this section

Diseases related to End Stage Renal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1175)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 3 34.7 PVT1 ALB ACE
2 alport syndrome 33.3 VEGFA MYH9 CFH ALB
3 microvascular complications of diabetes 5 33.1 VEGFA SOD2 PON1 ALB ACE
4 diabetes mellitus, type i 32.9 VEGFA SOD2 PVT1 PON1 IL1RN ALB
5 focal segmental glomerulosclerosis 5 32.9 APOL1 ACTN4
6 genetic steroid-resistant nephrotic syndrome 32.9 CD2AP APOL1 ACTN4
7 polycystic kidney disease 1 with or without polycystic liver disease 32.8 NEK8 INVS ACE
8 focal segmental glomerulosclerosis 2 32.2 CD2AP ACTN4
9 uremia 32.2 PON1 EPO ALB ACE
10 glomerulonephritis 32.1 MYH9 CFH APOL1 ALB ACE
11 vascular disease 31.9 VEGFA THBD PON1 EPO ALB ACE
12 peripheral vascular disease 31.8 VEGFA THBD EPO ALB ACE
13 congestive heart failure 31.8 VEGFA EPO ALB ACE
14 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 31.8 HFE EPO ALB
15 homocysteinemia 31.7 THBD PON1 ALB
16 sleep apnea 31.7 VEGFA EPO ALB ACE
17 polycystic kidney disease 31.7 VEGFA NEK8 INVS EPO ALB ACE
18 deficiency anemia 31.7 PON1 HFE EPO ALB ACE
19 kidney disease 31.7 THBD RNLS PON1 NEK8 MYH9 EPO
20 atherosclerosis susceptibility 31.7 VEGFA THBD PON1 ALB ACE
21 iga glomerulonephritis 31.6 CFH ALB ACE
22 pericarditis 31.6 IL1RN ALB ACE
23 glomerular disease 31.6 CD2AP ALB ACE
24 lipoprotein quantitative trait locus 31.5 VEGFA PON1 IL1RN ALB ACE
25 chronic kidney disease 31.5 VEGFA THBD RNLS PON1 MYH9 INVS
26 hypertensive nephropathy 31.5 VEGFA ALB ACE
27 nephrotic syndrome 31.5 CD2AP APOL1 ALB ACTN4 ACE
28 interstitial nephritis 31.5 INVS ALB ACE
29 pericardial effusion 31.4 VEGFA IL1RN ALB ACE
30 systemic lupus erythematosus 31.4 VEGFA THBD PON1 IL1RN CFH APOL1
31 ischemia 31.4 VEGFA SOD2 RNLS PON1 IL1RN EPO
32 focal segmental glomerulosclerosis 31.4 PON1 MYH9 CD2AP APOL1 ALB ACTN4
33 impotence 31.4 VEGFA ALB ACE
34 peripheral artery disease 31.4 VEGFA THBD ACE
35 malignant hypertension 31.3 THBD CFH ACE
36 peripheral nervous system disease 31.3 VEGFA EPO ALB ACE
37 coronary stenosis 31.3 PON1 ALB ACE
38 cystic kidney disease 31.3 NEK8 INVS EPO ALB ACE
39 thrombotic microangiopathy 31.3 VEGFA CFH
40 exanthem 31.2 VEGFA IL1RN ALB ACE
41 cardiac arrest 31.2 THBD EPO ALB ACE
42 porphyria cutanea tarda 31.2 HFE EPO ALB
43 iron deficiency anemia 31.2 PON1 HFE EPO
44 porphyria 31.2 HFE EPO ALB
45 antiphospholipid syndrome 31.1 THBD PON1 CFH
46 carpal tunnel syndrome 31.1 VEGFA IL1RN ACE
47 membranous nephropathy 31.1 CD2AP ALB ACE
48 respiratory failure 31.1 THBD IL1RN EPO ALB ACE
49 polyneuropathy 31.1 VEGFA EPO ALB ACE
50 pre-eclampsia 31.1 VEGFA THBD PON1 BDKRB2 ALB ACE

Graphical network of the top 20 diseases related to End Stage Renal Disease:



Diseases related to End Stage Renal Disease
Sources

Symptoms & Phenotypes for End Stage Renal Disease

About this section

MGI Mouse Phenotypes related to End Stage Renal Disease:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 ACE ACTN4 ALB BDKRB1 BDKRB2 CD2AP
2 homeostasis/metabolism MP:0005376 10.32 ACE ACTN4 ALB BDKRB1 BDKRB2 CD2AP
3 hematopoietic system MP:0005397 10.28 ACE ACTN4 BDKRB1 BDKRB2 CD2AP CFH
4 cellular MP:0005384 10.26 ACTN4 ALB BDKRB2 EPO HFE IL1RN
5 immune system MP:0005387 10.22 ACE ACTN4 ALB BDKRB1 BDKRB2 CD2AP
6 growth/size/body region MP:0005378 10.21 ACE ACTN4 CD2AP CFH HFE IL1RN
7 digestive/alimentary MP:0005381 10.06 ACTN4 ALB BDKRB2 HFE INVS NEK8
8 mortality/aging MP:0010768 10.03 ACE ACTN4 ALB BDKRB2 CD2AP CFH
9 liver/biliary system MP:0005370 9.91 ACE ACTN4 ALB EPO HFE INVS
10 normal MP:0002873 9.61 ALB BDKRB1 BDKRB2 CFH EPO HFE
11 renal/urinary system MP:0005367 9.4 ACE ACTN4 ALB BDKRB2 CD2AP CFH
Sources

Drugs & Therapeutics for End Stage Renal Disease

About this section

Drugs for End Stage Renal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 624)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capsaicin Approved Phase 4 404-86-4 1548943
2
Simvastatin Approved Phase 4 79902-63-9 54454
3
Eplerenone Approved Phase 4 107724-20-9 150310 443872
4
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
5
Digoxin Approved Phase 4 20830-75-5 30322 2724385
6
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
7
Promethazine Approved, Investigational Phase 4 60-87-7 4927
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
10
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
11
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
12
Hydroxychloroquine Approved Phase 4 118-42-3 3652
13
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
14
Glimepiride Approved Phase 4 93479-97-1 3476
15
Nifedipine Approved Phase 4 21829-25-4 4485
16
Methyldopa Approved Phase 4 555-30-6 38853
17
Ticlopidine Approved Phase 4 55142-85-3 5472
18
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
19
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
20
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
21
Ramipril Approved Phase 4 87333-19-5 5362129
22
Cinacalcet Approved Phase 4 226256-56-0 156419
23
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
24
Ribavirin Approved Phase 4 36791-04-5 37542
25
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
26
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
27
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
28
Allopurinol Approved Phase 4 315-30-0 2094
29
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
30
Ticagrelor Approved Phase 4 274693-27-5 9871419
31
Colchicine Approved Phase 4 64-86-8 2833 6167
32
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
33
Donepezil Approved Phase 4 120014-06-4 3152
34
alemtuzumab Approved, Investigational Phase 4 216503-57-0
35
Telavancin Approved Phase 4 372151-71-8
36
Enoxaparin Approved Phase 4 9005-49-6 772
37
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
38
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
39
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
40
Rivaroxaban Approved Phase 4 366789-02-8
41
Insulin aspart Approved Phase 4 116094-23-6 16132418
42
Nitric Oxide Approved Phase 4 10102-43-9 145068
43
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
44
Pantoprazole Approved Phase 4 102625-70-7 4679
45
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
46
Phylloquinone Approved, Investigational Phase 4 84-80-0
47 Taurolidine Approved, Investigational Phase 4 19388-87-5
48
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
49
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
50
Remifentanil Approved Phase 4 132875-61-7 60815

Interventional clinical trials:

(show top 50) (show all 2004)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
2 Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial Unknown status NCT00541814 Phase 4 Cyclosporine
3 Comparison of Onset of Action Between 2% Lidocaine Plus 0.5% Bupivacaine and 0.5% Bupivacaine in Brachial Plexus Anesthesia for Creation of Arteriovenous Fistula in ESRD Patient Unknown status NCT00993746 Phase 4 Bupivacaine plus lidocaine;Bupivacaine 30 ml
4 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
5 A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery Unknown status NCT02447796 Phase 4 Propofol;Dexmedetomidine
6 Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients Unknown status NCT00532597 Phase 4
7 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
8 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
9 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
10 A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD) Unknown status NCT02502981 Phase 4 Spironolactone;Chlortalidone
11 The Association Between Body Composition and Biomarkers in Hemodialysis Patients Unknown status NCT01103167 Phase 4
12 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
13 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
14 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
15 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
16 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
17 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
18 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
19 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
20 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
21 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
22 The Efficacy and Safety of Nicotinic Acid in the Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
23 AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study Unknown status NCT03005236 Phase 4 ENVARSUS;Standard twice daily tacrolimus
24 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
25 Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus Unknown status NCT01073501 Phase 4 Pregabalin;Placebo
26 Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients Unknown status NCT01570556 Phase 4
27 N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
28 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
29 A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy Unknown status NCT03320031 Phase 4 Linagliptin;Humalog Mix 75/25
30 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
31 A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation Unknown status NCT00807144 Phase 4 Tacrolimus (Kidney transplant maintenance immunosuppression);Kidney transplant maintenance immunosuppression
32 Lithium in Cardiac Surgery Related Acute Kidney Injury: A Pilot Study Unknown status NCT03056248 Phase 4 Placebo oral capsule;Lithium Carbonate
33 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
34 Effect of Short-term Synbiotic Treatment on Plasma P-cresol Levels in Hemodialysis Patients Unknown status NCT02311868 Phase 4
35 Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis Unknown status NCT01228279 Phase 4
36 Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease Unknown status NCT02452437 Phase 4 Oxycodone
37 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4
38 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
39 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
40 Hypervolemia and Treatment Guided by Bioimpedance in End Stage Renal Disease Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4
41 A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
42 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
43 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
44 The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
45 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
46 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
47 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
48 Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation Unknown status NCT01729494 Phase 4 Alemtuzumab;rabbit antithymocyte globulin;Belatacept;Tacrolimus;Mycophenolate mofetil;early cessation of steroids
49 Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney. Unknown status NCT01208714 Phase 4 Optimal medical therapy
50 Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Unknown status NCT00553722 Phase 4 Eplerenone;Placebo

Search NIH Clinical Center for End Stage Renal Disease

Sources

Genetic Tests for End Stage Renal Disease

About this section
Sources

Anatomical Context for End Stage Renal Disease

About this section

MalaCards organs/tissues related to End Stage Renal Disease:

40
Kidney, Heart, Bone, Liver, Pancreas, Endothelial, Testes
Sources

Publications for End Stage Renal Disease

About this section

Articles related to End Stage Renal Disease:

(show top 50) (show all 35586)
# Title Authors PMID Year
1
Dialysis patients who smoke are more hypertensive, more fluid overloaded and take more antihypertensive medications than nonsmokers. 61
32349634 2020
2
Predialysis nephrology care amongst Palestinian hemodialysis patients and its impact on initial vascular access type. 61
32506996 2020
3
Late diagnosis of Lesch-Nyhan disease complicated with end-stage renal disease and tophi burst: a case report. 61
31985336 2020
4
Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis. 61
31918608 2020
5
Association between epidermal growth factor (EGF) and EGF receptor gene polymorphisms and end-stage renal disease and acute renal allograft rejection in a Korean population. 61
31906817 2020
6
Meta-Analysis Treatment Hyperphosphatemia Chronic Renal Failure Based on Nano Lanthanum Hydroxide. 61
32385013 2020
7
Soluble ST2: A complex and diverse role in several diseases. 61
32305537 2020
8
Molecular pathways involved in injury-repair and ADPKD progression. 61
32320858 2020
9
Sleeve Gastrectomy Attenuates Diabetic Nephropathy by Upregulating Nephrin Expressions in Diabetic Obese Rats. 61
32399849 2020
10
Intraoperative Ultrasound Guidance for Banding of an Arteriovenous Fistula Causing High Cardiac Output Heart Failure. 61
31863947 2020
11
Racial and Ethnic Disparities in Kidney Transplant Access Within a Theoretical Context of Medical Eligibility. 61
31568216 2020
12
Midterm outcomes of brachial arterio-arterial prosthetic loop as permanent hemodialysis access. 61
31987667 2020
13
Self-Care Behavior Profiles With Arteriovenous Fistula in Hemodialysis Patients. 61
29986608 2020
14
Distinct Symptom Experience Among Subgroups of Patients With ESRD Receiving Maintenance Dialysis. 61
31981596 2020
15
Early Delays in Insurance Coverage and Long-term Use of Home-based Peritoneal Dialysis. 61
32520837 2020
16
Compensatory Changes in Parenchymal Mass and Function after Radical Nephrectomy. 61
32073996 2020
17
Predictors of Major Adverse Limb Events after Open Forefoot Amputation in Patients with Chronic Limb-Threatening Ischemia. 61
32027986 2020
18
Multidisciplinary Medication Therapy Management and Hospital Readmission in Patients Undergoing Maintenance Dialysis: A Retrospective Cohort Study. 61
32173107 2020
19
Comparison of Clinical Performance of VectorFlow and Palindrome Symmetric-Tip Dialysis Catheters: A Multicenter, Randomized Trial. 61
32534972 2020
20
Blood flow quantification in dialysis access using digital subtraction angiography: A retrospective study. 61
32050137 2020
21
The Controlling Nutritional Status Score is Significantly Associated with Complete Ulcer Healing in Patients with Critical Limb Ischemia. 61
31917224 2020
22
Hesperetin inhibit EMT in TGF-β treated podocyte by regulation of mTOR pathway. 61
32451085 2020
23
T lymphocytes in IgA nephropathy. 61
32509008 2020
24
Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren's syndrome? 61
31720749 2020
25
Abdominal aortic calcification in predialysis patients: Contribution of traditional and uremia-related risk factors. 61
32509000 2020
26
High incidence of urinary tract infections after photoselective laser vaporisation of the prostate: a risk factor analysis of 665 patients. 61
31578631 2020
27
Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. 61
31939197 2020
28
Brazilian consensus on vesicoureteral reflux-recommendations for clinical practice. 61
32167732 2020
29
Clinical and pathological features and varied mutational spectra of pathogenic genes in 55 Chinese patients with nephronophthisis. 61
32173348 2020
30
Implications of immunoglobulin G deposit in glomeruli in Chinese patients with diabetic nephropathy. 61
32031751 2020
31
Hyperuricemia is associated with decreased renal function and occurrence of end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective study. 61
32314011 2020
32
Infection with hepatitis C virus in hemodialysis patients: An overview of the diagnosis and prevention rules within a hemodialysis center (Review). 61
32509002 2020
33
Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway. 61
32348836 2020
34
The effect of hemodialysis, peritoneal dialysis and renal transplantation on nutritional status and serum micronutrient levels in patients with end-stage renal disease; Multicenter, 6-month period, longitudinal study. 61
32220765 2020
35
Vascular access creation in octogenarians: The effect of age on outcomes. 61
31882312 2020
36
Implications of early failure of isolated endovascular tibial interventions. 61
32035771 2020
37
End-stage renal disease meets end-of-the-line access. 61
32553400 2020
38
Burden of living with multiple concurrent symptoms in patients with end-stage renal disease. 61
32279368 2020
39
Changes in redox state of albumin before and after kidney transplantation in patients with end-stage renal disease. 61
32380091 2020
40
Expansion of Group 2 Innate Lymphoid Cells in Patients with End-Stage Renal Disease and Their Clinical Significance. 61
32444391 2020
41
Effect of a Virtual Reality-Based Exercise Program on Fatigue in Hospitalized Taiwanese End-Stage Renal Disease Patients Undergoing Hemodialysis. 61
30009636 2020
42
Quality of Care in Chronic Kidney Disease and Incidence of End-stage Renal Disease in Older Patients: A Cohort Study. 61
31985583 2020
43
Estimation of population-based utility weights for health states of chronic kidney disease, dialysis and kidney transplantation. 61
32026549 2020
44
Talaromyces (Penicillium) species infection in the central nervous system. 61
32568283 2020
45
Effects of periodontal disease on glycemic control, complications, and incidence of diabetes mellitus. 61
32385875 2020
46
Hospital Charges Associated with Central Venous Stenosis in Pediatric Patients Requiring Long-Term Central Venous Access. 61
32446474 2020
47
Post-contrast acute kidney injury in a hospitalized population: short-, mid-, and long-term outcome and risk factors for adverse events. 61
32080754 2020
48
ε2 allele and ε2-involved genotypes (ε2/ε2, ε2/ε3, and ε2/ε4) may confer the association of APOE genetic polymorphism with risks of nephropathy in type 2 diabetes: a meta-analysis. 61
32534589 2020
49
ASSOCIATION OF DIAGNOSIS CODE-BASED AND LABORATORY RESULTS-BASED KIDNEY FUNCTION WITH DEVELOPMENT OF VISION THREATENING DIABETIC RETINOPATHY. 61
32500786 2020
50
Effect of Glomerulopathy Recurrence in the Outcome and Graft Survival of Kidney Transplanted Patients. 61
32245622 2020
Sources

Variations for End Stage Renal Disease

About this section
Sources

Expression for End Stage Renal Disease

About this section
Search GEO for disease gene expression data for End Stage Renal Disease.
Sources

Pathways for End Stage Renal Disease

About this section

Pathways related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 60
Show member pathways
 11.23 BDKRB2 BDKRB1 ACE
2
Complement and coagulation cascades 36 1
11.09 THBD CFH BDKRB2 BDKRB1
3
Primary Focal Segmental Glomerulosclerosis FSGS 1
11 MYH9 CD2AP ACTN4
Sources

GO Terms for End Stage Renal Disease

About this section

Cellular components related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 SOD2 PON1 MYH9 IL1RN CFH CD2AP
2 extracellular region GO:0005576 9.96 VEGFA RNLS PON1 IL1RN EPO CFH
3 platelet alpha granule lumen GO:0031093 9.54 VEGFA ALB ACTN4
4 blood microparticle GO:0072562 9.46 PON1 CFH APOL1 ALB
5 extracellular space GO:0005615 9.4 VEGFA THBD RNLS PON1 IL1RN HFE
6 ciliary inversin compartment GO:0097543 8.96 NEK8 INVS

Biological processes related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of leukocyte migration GO:0002687 9.32 VEGFA BDKRB1
2 positive regulation of cellular component movement GO:0051272 9.26 VEGFA ACTN4
3 response to salt stress GO:0009651 9.16 EPO BDKRB2
4 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 8.96 EPO BDKRB2
5 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 8.62 VEGFA ACE

Molecular functions related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor receptor binding GO:0005172 8.96 VEGFA CD2AP
2 bradykinin receptor activity GO:0004947 8.62 BDKRB2 BDKRB1
Sources

Sources for End Stage Renal Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....